Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CE 008
- Development stage
- Preclinical
- Lead developer
- Cello Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
CE 008 is a cellular nanoparticle (CNP) chemotherapy drug under development by Cello Therapeutics. It is classified as an antineoplastic and drug conjugate, designed for the treatment of colorectal cancer and gastric cancer. The precise mechanism of action has not been defined or disclosed publicly. As a new molecular entity, it represents an innovative approach in oncology therapeutics utilizing membrane-encapsulated nanoparticles to potentially enhance delivery and efficacy of chemotherapeutic agents[2].
Beyond the preview
Go deeper on CE 008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CE 008.